CX-801 for Advanced Solid Tumors
First In Human Study of CX-801 in Advanced Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 121 (estimated)
- Sponsor
- CytomX Therapeutics · Industry
This trial is looking for adults with advanced solid tumors that have not responded to standard treatments. Participants will receive the study drug CX-801, which can be given alone or with another treatment called pembrolizumab.
You may be able to join if
- I have a solid tumor that has spread or cannot be surgically removed.
- I have worsening disease after standard treatment.
- I have a performance status of 0-1.
- I have measurable disease.
- I consent to a fresh biopsy or have recent tumor tissue available.
- I have adequate organ function.
You may not be able to join if
- I have had localized cancers not related to my current cancer in the last 2 years.
- I have known active cancer in my brain or spine.
- I was treated with PD-1 or PD-(L)1 inhibitors and stopped due to severe side effects.
- I have had systemic cancer treatment within the last 4 weeks.
- I have used an investigational drug or device in the last 4 weeks.
- I have received radiation treatment in the last 2 weeks.
- I have a serious illness that could interfere.
- I am pregnant or breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
Loading trial locations…